[Therapeutic use of antimycotic substances].
Since secondary deep mycoses are frequently seen in internal medicine nowadays, increasing interest has been focused on antimycotic therapy. This report deals with the limited available range of antimycotic substances which can be administered systemically. Since severe adverse effects are often observed with Amphotericin-B, the most effective antifungal agent, the advent of three new systemic antifungal drugs (Clotrimazole, Miconazole, 5-Fluorocytosine) has proven to be a real advance in our therapeutic approach to deep mycoses. To avoid unwanted side-effects, combined therapy with low doses of Amphotericin-B and another antimycotic agent promises to become increasingly important.
D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000935:Antifungal Agents / Q000627:therapeutic use*; D002056:Burns / Q000150:complications; D006348:Cardiac Surgical Procedures / Q000009:adverse effects; D002404:Catheterization / Q000009:adverse effects; D003022:Clotrimazole / Q000627:therapeutic use; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008825:Miconazole / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy / Q000209:etiology
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D008825:Miconazole; D000666:Amphotericin B; D005437:Flucytosine; D003022:Clotrimazole
Zur therapeutischen Anwendung antimykotischer Substanzen